Sharecast News
08 Apr, 2022 16:17

Avacta joint venture enters new immune model collaboration

dl avacta aim life science sciences logo
AvactaSharecast graphic / Josh White

Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

The AIM-traded firm said the collaboration was aimed at developing new immune disease in-vivo models, and carrying out proof-of-concept and toxicity testing of AffyXell's drug candidates using the developed disease models.

It said the new models would benefit from Biocytogen's platform for gene editing, which created mouse models capable of producing human antibodies.

The collaboration was designed to improve the translation of AffyXell's programmes into human trials, and accelerate drug development.

Avacta said KNTSC's role in the collaboration would be to provide the infrastructure and overall management for pre-clinical trials.

“The quality of pre-clinical disease models and their ability to translate into humans is critical for reducing risk and timelines associated with drug development,” said Avacta chief executive officer Dr Alastair Smith.

“This collaboration has the potential to significantly accelerate AffyXell's programmes.”

At 1600 BST, shares in Avacta Group were up 12.55% at 100.17p.


News Source: © 2022 Web Financial Group (UK) Limited. All rights reserved and terms of use apply.

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

 

Important Legal Notice about News Sources

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.